Prelude Capital Management’s Puma Biotechnology PBYI Stock Holding History
Bought
Maintained
Sold
Other funds holding PBYI
ACA
Prelude Capital Management's PBYI Position: Q3 2026 in Review
Prelude Capital Management reduced its Puma Biotechnology (PBYI) stake by 11% in Q3 2026, selling an estimated $20.2K and leaving 19,248 shares worth $191K. The position accounts for 0.01% of the portfolio, ranked #1116.
Prelude Capital Management first reported a position in PBYI in Q1 2015 and has held it in 16 quarters since. The position peaked at $1.22M in Q4 2017. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2026.
- Prelude Capital Management held 19,248 shares of Puma Biotechnology worth $191K as of Q3 2026.
- Prelude Capital Management sold 2,300 Puma Biotechnology shares in Q3 2026, an estimated $20.2K.
- Puma Biotechnology made up 0.01% of Prelude Capital Management's portfolio in Q3 2026, its #1116 holding.
- Prelude Capital Management first reported a position in Puma Biotechnology in Q1 2015 and has held it in 16 quarters since.
- Prelude Capital Management's Puma Biotechnology position peaked at $1.22M in Q4 2017.
- 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2026.
Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.